/CBIA

CBIA Stock - Canopus BioPharma Incorporated

Q: What is the analyst price target for CBIA?

Analyst price target information is not currently available for CBIA.

Q: What is CBIA's market cap?

Market capitalization information is not currently available for CBIA.

Financial Services|Shell Companies|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CBIA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2012

FY2013

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta8.28

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2013	FY2012
Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	$-9,873	$-9,873
Gross Margin	N/A	N/A	N/A	N/A
Operating Income	$-764,560	$-1,760	$-510,170	$-118,430
Net Income	$-764,708	$-1,755	$-850,936	$-525,939
Net Margin	N/A	N/A	N/A	N/A
EPS	$-0.01	$0.00	$-0.02	$-0.02

Company Overview

Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and changed its name in 2007. Canopus BioPharma Incorporated is based in Santa Monica, California.

Visit Website

Frequently Asked Questions about CBIA

What is CBIA's current stock price?

Canopus BioPharma Incorporated (CBIA) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for CBIA?

No analyst price targets are currently available for this stock.

What sector is Canopus BioPharma Incorporated in?

Canopus BioPharma Incorporated operates in the Financial Services sector, specifically within the Shell Companies industry. The company is traded on the OTC exchange.

What is CBIA's market cap?

Canopus BioPharma Incorporated has a market capitalization of $0.00 billion, making it a small-cap company.

Does CBIA pay dividends?

No, Canopus BioPharma Incorporated does not currently pay a dividend to shareholders.